Abstract
Metastatic relapse is responsible for 90% of cancer-related deaths. The process of distant spreading is a cascade of events that is regulated in a highly complex manner; one cellular phenomenon underlying all the events is cytoskeletal reorganisation. Despite the fact that the ability to leave the primary site and establish a viable mass in a distant site is a hallmark of cancer, targeting cytoskeletal reorganisation is an emerging field. In this review we describe the key signalling pathways controlling cytoskeletal reorganisation and the current targeted therapies against the “druggable” nodes. Finally, we discuss potential implications of trial design that can play a role in detecting the specific activity of this drug class.
Similar content being viewed by others
References
Christofori G (2006) New signals from the invasive front. Nature 441:444–450
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676
Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139
Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042
Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–572
Boyer B, Tucker GC, Valles AM et al (1989) Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 109:1495–1509
Wang W, Eddy R, Condeelis J (2007) The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 7:429–440
Wang W, Wyckoff JB, Goswami S et al (2007) Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. Cancer Res 67: 3505–3511
Wang W, Goswami S, Sahai E et al (2005) Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 15:138–145
Ono S (2007) Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics. Int Rev Cytol 258:1–82
Maciver SK, Hussey PJ (2002) The ADF/cofilin family: actin-remodeling proteins. Genome Biol 3:reviews3007
Ghosh M, Song X, Mouneimne G et al (2004) Cofilin promotes actin polymerization and defines the direction of cell motility. Science 304:743–746
Hotulainen P, Paunola E, Vartiainen MK et al (2005) Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells. Mol Biol Cell 16:649–664
Mogilner A, Oster G (2003) Polymer motors: pushing out the front and pulling up the back. Curr Biol 13:R721–733
dos Remedios CG, Chhabra D, Kekic M et al (2003) Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83:433–473
Yamaguchi H, Lorenz M, Kempiak S et al (2005) Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 168:441–452
Wang W, Mouneimne G, Sidani M et al (2006) The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol 173:395–404
Ichetovkin I, Han J, Pang KM et al (2000) Actin filaments are severed by both native and recombinant dictyostelium cofilin but to different extents. Cell Motil Cytoskeleton 45:293–306
Ichetovkin I, Grant W, Condeelis J (2002) Cofilin produces newly polymerized actin filaments that are preferred for dendritic nucleation by the Arp2/3 complex. Curr Biol 12:79–84
Andrianantoandro E, Pollard TD (2006) Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin. Mol Cell 24:13–23
Bamburg JR, Wiggan OP (2002) ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12: 598–605
Dan C, Kelly A, Bernard O et al (2001) Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem 276:32115–32121
Okano I, Hiraoka J, Otera H et al (1995) Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. J Biol Chem 270:31321–31330
Yang N, Higuchi O, Ohashi K et al (1998) Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 393:809–812
Toshima J, Toshima JY, Takeuchi K et al (2001) Cofilin phosphorylation and actin reorganization activities of testicular protein kinase 2 and its predominant expression in testicular Sertoli cells. J Biol Chem 276:31449–31458
Toshima J, Toshima JY, Amano T et al (2001) Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation. Mol Biol Cell 12:1131–1145
Niwa R, Nagata-Ohashi K, Takeichi M et al (2002) Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. Cell 108:233–246
Meberg PJ, Ono S, Minamide LS et al (1998) Actin depolymerizing factor and cofilin phosphorylation dynamics: response to signals that regulate neurite extension. Cell Motil Cytoskeleton 39: 172–190
Ambach A, Saunus J, Konstandin M et al (2000) The serine phosphatases PP1 and PP2A associate with and activate the actin-binding protein cofilin in human T lymphocytes. Eur J Immunol 30:3422–3431
Gohla A, Birkenfeld J, Bokoch GM (2005) Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics. Nat Cell Biol 7:21–29
Goldberg Y (1999) Protein phosphatase 2A: who shall regulate the regulator? Biochem Pharmacol 57:321–328
Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417–439
Yonezawa N, Homma Y, Yahara I et al (1991) A short sequence responsible for both phosphoinositide binding and actin binding activities of cofilin. J Biol Chem 266:17218–17221
Yonezawa N, Nishida E, Iida K et al (1990) Inhibition of the interactions of cofilin, destrin, and deoxyribonuclease I with actin by phosphoinositides. J Biol Chem 265:8382–8386
Mouneimne G, DesMarais V, Sidani M et al (2006) Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis. Curr Biol 16:2193–2205
Devreotes P, Janetopoulos C (2003) Eukaryotic chemotaxis: distinctions between directional sensing and polarization. J Biol Chem 278:20445–20448
Schaller MD (2001) Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540:1–21
Hsia DA, Lim ST, Bernard-Trifilo JA et al (2005) Integrin alpha4beta1 promotes focal adhesion kinase-independent cell motility via alpha4 cytoplasmic domain-specific activation of c-Src. Mol Cell Biol 25:9700–9712
Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56–68
Angelucci A, Bologna M (2007) Targeting vascular cell migration as a strategy for blocking angiogenesis: the central role of focal adhesion protein tyrosine kinase family. Curr Pharm Des 13:2129–2145
Schwock J, Dhani N, Hedley DW (2010) Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opin Ther Targets 14:77–94
Avizienyte E, Wyke AW, Jones RJ et al (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4:632–638
Cicchini C, Laudadio I, Citarella F et al (2008) TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res 314:143–152
van Nimwegen MJ, Verkoeijen S, van Buren L et al (2005) Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation. Cancer Res 65:4698–4706
Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Luo M, Fan H, Nagy T et al (2009) Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 69:466–474
Luo M, Guan JL (2010) Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 289:127–139
Slack-Davis JK, Martin KH, Tilghman RW et al (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282: 14845–14852
Roberts WG, Ung E, Whalen P et al (2008) Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68:1935–1944
Siu LL, Burris HA, Mileshkin L et al (2007) Phase I study of focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I, Vol 25:3527
A study of PF-04554878 in patients with advanced non-hematologic malignancies (B0761001). http://clinicaltrials.gov/ct2/show/NCT00787033?term=FAK+inhibitor&rank=3
Beierle EA, Trujillo A, Nagaram A et al (2008) TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 26:145–151
Golubovskaya VM, Virnig C, Cance WG (2008) TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 47:222–234
Sakurama K, Noma K, Takaoka M et al (2009) Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther 8:127–134
Study of a focal adhesion kinase inhibitor in subjects with solid tumors. http://clinicaltrials.gov/ct2/show/NCT01138033?term=FAK+inhibitor&rank=1
Sieg DJ, Hauck CR, Ilic D et al (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256
Carragher NO, Walker SM, Scott Carragher LA et al (2006) Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function. Oncogene 25:5726–5740
Biscardi JS, Tice DA, Parsons SJ (1999) c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76:61–119
Jove R, Hanafusa H (1987) Cell transformation by the viral src oncogene. Annu Rev Cell Biol 3:31–56
Wang E, Goldberg AR (1976) Changes in microfilament organization and surface topography upon transformation of chick embryo fibroblasts with Rous sarcoma virus. Proc Natl Acad Sci U S A 73:4065–4069
Parsons JT, Weber MJ (1989) Genetics of src: structure and functional organization of a protein tyrosine kinase. Curr Top Microbiol Immunol 147:79–127
Bjorge JD, Jakymiw A, Fujita DJ (2000) Selected glimpses into the activation and function of Src kinase. Oncogene 19:5620–5635
Laukaitis CM, Webb DJ, Donais K et al (2001) Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol 153:1427–1440
Guarino M (2010) Src signaling in cancer invasion. J Cell Physiol 223:14–26
Guarino M (1995) Epithelial-to-mesenchymal change of differentiation. From embryogenetic mechanism to pathological patterns. Histol Histopathol 10:171–184
Guarino M (2007) Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39:2153–2160
Guarino M, Rubino B, Ballabio G (2007) The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305–318
Behrens J, Vakaet L, Friis R et al (1993) Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 120:757–766
Niu G, Bowman T, Huang M et al (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21:7001–7010
Malek RL, Irby RB, Guo QM et al (2002) Identification of Src transformation fingerprint in human colon cancer. Oncogene 21:7256–7265
Blake RA, Broome MA, Liu X et al (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20:9018–9027
Sekharam M, Nasir A, Kaiser HE et al (2003) Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 23:1517–1524
Kim LC, Song L, Haura EB (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587–595
Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354: 2531–2541
Shah NP, Tran C, Lee FY et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399–401
Lindauer M, Hochhaus A (2010) Dasatinib. Recent Results Cancer Res 184:83–102
Trevino JG, Summy JM, Lesslie DP et al (2006) Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168:962–972
Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800–2808
Tsao AS, He D, Saigal B et al (2007) Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6:1962–1972
Timeus F, Crescenzio N, Fandi A et al (2008) In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol Rep 19:353–359
Park SI, Zhang J, Phillips KA et al (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68:3323–3333
Pichot CS, Hartig SM, Xia L et al (2009) Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101:38–47
Choi YL, Bocanegra M, Kwon MJ et al (2010) LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70:2296–2306
Zhang XH, Wang Q, Gerald W et al (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16:67–78
Herynk MH, Beyer AR, Cui Y et al (2006) Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol Cancer Ther 5:3023–3031
Golas JM, Lucas J, Etienne C et al (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 65:5358–5364
Messersmith WA, Krishnamurthi S, Hewes BA et al (2007) Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25(18S):3552
Lara PN Jr, Longmate J, Evans CP et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20:179–184
Haura EB, Tanvetyanon T, Chiappori A et al (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28:1387–94
Miller AA, Pang H, Hodgson L et al (2010) A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 5:380–384
Yu EY, Wilding G, Posadas E et al (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421–7428
Schenone S, Manetti F, Botta M (2007) Synthetic SRC-kinase domain inhibitors and their structural requirements. Anticancer Agents Med Chem 7:660–680
Frank C, Burkhardt C, Imhof D et al (2004) Effective dephosphorylation of Src substrates by SHP-1. J Biol Chem 279:11375–11383
Ye G, Tiwari R, Parang K (2008) Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs 9:605–613
Lau GM, Yu GL, Gelman IH et al (2009) Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci 54: 1465–1474
KX2-391 in treating patients with advanced solid tumors or lymphoma that did not tespond to treatment. http://clinicaltrials.gov/ct2/show/NCT00646139?term=KX2-391&rank=2
Evaluation of KX2-391 in patients with advanced malignancies. http://clinicaltrials.gov/ct2/show/NCT00658970?term=KX2-391&rank=3
A safety and efficacy study of KX2-391 in patients with bone-metastatic, castration-resistant prostate cancer who have not received prior chemotherapy. http://clinicaltrials.gov/ct2/show/NCT01074138?term=KX2-391&rank=1
Riento K, Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446–456
Takayasu M, Suzuki Y, Shibuya M et al (1986) The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs. J Neurosurg 65:80–85
Ying H, Biroc SL, Li WW et al (2006) The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5:2158–2164
Yin L, Morishige K, Takahashi T et al (2007) Fasudil inhibits vascular endothelial growth factorinduced angiogenesis in vitro and in vivo. Mol Cancer Ther 6:1517–1525
Yang X, Liu Y, Zong Z et al (2010) The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. Biomed Pharmacother 64:58–62
Ogata S, Morishige K, Sawada K et al (2009) Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int J Gynecol Cancer 19:1473–1480
Deng L, Li G, Li R et al (2010) Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. Cancer Biol Ther 9:875–884
Mahlamaki EH, Kauraniemi P, Monni O et al (2004) High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia 6: 432–439
Kim JH, Kim HN, Lee KT et al (2008) Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis. Tumour Biol 29:41–49
Wells CM, Abo A, Ridley AJ (2002) PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci 115:3947–3956
Eswaran J, Soundararajan M, Knapp S (2009) Targeting group II PAKs in cancer and metastasis. Cancer Metastasis Rev 28:209–217
Callow MG, Clairvoyant F, Zhu S et al (2002) Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem 277:550–558
Murray BW, Guo C, Piraino J et al (2010) Smallmolecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 107:9446–9451
This is the first study using escalating doses of PF-03758309, an oral compound, in patients with advanced solid tumors. http://clinicaltrials.gov/ct2/show/NCT00932126?term=PAK4&rank=1
Quintela-Fandino M, Arpaia E, Brenner D et al (2010) HUNK suppresses metastasis of basal type breast cancers by disrupting the interaction between PP2A and cofilin-1. Proc Natl Acad Sci U S A 107:2622–2627
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Quintela-Fandino, M., González-Martín, A. & Colomer, R. Targeting cytoskeleton reorganisation as antimetastatic treatment. Clin Transl Oncol 12, 662–669 (2010). https://doi.org/10.1007/s12094-010-0575-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-010-0575-8